Evidence map›Paper›PMID 33606091›Full record

ArticleArchives of gynecology and obstetrics2021

Fertility preserving management of early endometrial cancer in a patient cohort at the department of women's health at the university of Tuebingen.

Jürgen Andress, Jana Pasternak, Christina Walter, Stefan Kommoss, Bernhard Krämer, Andreas Hartkopf, Sara Yvonne Brucker, Birgitt Schönfisch, Sahra Steinmacher

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of gynecology and obstetrics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 3 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 3 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Article
  7. The Advance and Correlation ofPathology oncology research : POR · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Jürgen AndressDepartment of Women'S Health, Tuebingen University Hospital, Calwerstr. 7, 72076, Tuebingen, Germany. juergen.andress@med.uni-tuebingen.de.
Jana PasternakDepartment of Women'S Health, Tuebingen University Hospital, Calwerstr. 7, 72076, Tuebingen, Germany.
Christina WalterDepartment of Women'S Health, Tuebingen University Hospital, Calwerstr. 7, 72076, Tuebingen, Germany.
Stefan KommossDepartment of Women'S Health, Tuebingen University Hospital, Calwerstr. 7, 72076, Tuebingen, Germany.
Bernhard KrämerDepartment of Women'S Health, Tuebingen University Hospital, Calwerstr. 7, 72076, Tuebingen, Germany.
Andreas HartkopfDepartment of Women'S Health, Tuebingen University Hospital, Calwerstr. 7, 72076, Tuebingen, Germany.
Sara Yvonne BruckerDepartment of Women'S Health, Tuebingen University Hospital, Calwerstr. 7, 72076, Tuebingen, Germany.
Birgitt SchönfischDepartment of Women'S Health, Tuebingen University Hospital, Calwerstr. 7, 72076, Tuebingen, Germany.
Sahra SteinmacherDepartment of Women'S Health, Tuebingen University Hospital, Calwerstr. 7, 72076, Tuebingen, Germany.ORCID 0000-0003-1933-517X
University of Tübingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo investigate the oncologic and reproductive outcome of a conservative treatment with progestin agents in early-stage grade 1 endometrial cancer (G1EC), grade 2 endometrial cancer (G2EC) or complex atypical hyperplasia (CAH) in young premenopausal women.

methodsWomen treated for early-stage endometrial cancer or atypical hyperplasia of the endometrium with a conservative therapy between 2006 and 2018 were enrolled in this retrospective analysis. Progestin agents were orally administered on a daily basis for 3 months for at least one cycle. Endometrial tissue was obtained by hysteroscopy and Dilatation & Curettage (D&C) being performed before and after end of treatment. Therapeutic response was assessed by pathological examination.

resultsA total of 14 patients were included. After treatment with progestin agents, 11 of these patients initially showed a complete or partial response. Three patients with early-stage endometrial cancer did not respond. Of the three patients with initially diagnosed atypical hyperplasia, none showed any remaining disease later. Of the eight patients with initially diagnosed endometrial cancer, who had responded to first treatment, three patients were re-diagnosed with endometrial cancer later. One patient with initial endometrial cancer became pregnant but aborted in the 10th week.

conclusionDue to its good efficacy, progestin agents offer a feasible therapeutic option in the fertility-preserving treatment of early-stage endometrial cancer in young premenopausal women. However, recurrence rate remains high. Therefore, a close follow-up is mandatory, also in responders. Patients should be informed of limitations and risks of conservative treatment. Yet after completion of family planning, hysterectomy should be performed.

Indexed as

AdultAntineoplastic Agents, HormonalConservative TreatmentEndometrial HyperplasiaEndometrial NeoplasmsFemaleFertilityFertility PreservationGermanyHumansOrgan Sparing TreatmentsPregnancyProgestinsRetrospective StudiesTreatment OutcomeAntineoplastic Agents, HormonalProgestinsComplex atypical hyperplasiaFertility sparing treatmentLow-grade endometrial cancerProgestin agents

Identifiers

PMID33606091
PMCPMC8164611
OpenAlexW3129628846

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.